General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Quarterly results

Q1 2013 results - Wednesday, April 24, 2013


Media release

Q1 2013
(USD m)
Q1 2012
(USD m)
% change
Net sales14,01613,7352 (cc: 4)
Operating income2,8962,7366 (cc: 10)
Net income2,4222,2697 (cc: 13)
EPS (USD)0.980.935 (cc: 12)
Free cash flow21,2982,056-37

Operating income3,7143,6073 (cc: 6)
Net income3,2483,0357 (cc: 10)
EPS (USD)1.321.256 (cc: 9)

  1. Constant currencies
  2. Core results and free cash flow are non-IFRS measures. See media release for further information.

View archived presentations and webcasts from past events

The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Stock chart
Q3 Results 2013

On Thursday, April 24, Novartis will announce its results for the first quarter of 2014